Your browser is no longer supported. Please, upgrade your browser.
CMRX Chimerix, Inc. daily Stock Chart
Chimerix, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own1.10% Shs Outstand61.74M Perf Week0.31%
Market Cap207.11M Forward P/E- EPS next Y-0.25 Insider Trans23.70% Shs Float50.45M Perf Month3.86%
Income-105.30M PEG- EPS next Q-0.17 Inst Own54.10% Short Float2.48% Perf Quarter17.03%
Sales11.40M P/S18.17 EPS this Y-41.90% Inst Trans0.36% Short Ratio1.96 Perf Half Y82.49%
Book/sh1.64 P/B1.97 EPS next Y66.70% ROA-81.30% Target Price- Perf Year7.67%
Cash/sh1.61 P/C2.01 EPS next 5Y- ROE-89.20% 52W Range1.19 - 3.88 Perf YTD59.11%
Dividend- P/FCF- EPS past 5Y-2.40% ROI-105.20% 52W High-16.86% Beta1.92
Dividend %- Quick Ratio16.00 Sales past 5Y25.40% Gross Margin- 52W Low171.43% ATR0.23
Employees43 Current Ratio16.00 Sales Q/Q-50.00% Oper. Margin- RSI (14)47.98 Volatility7.90% 7.53%
OptionableYes Debt/Eq0.00 EPS Q/Q51.50% Profit Margin- Rel Volume0.59 Prev Close3.41
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume637.43K Price3.23
Recom2.30 SMA20-2.89% SMA500.29% SMA20044.16% Volume373,783 Change-5.28%
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Feb-02-18Initiated H.C. Wainwright Buy $10
Aug-09-16Reiterated FBR Capital Mkt Perform $9 → $8
Feb-23-16Reiterated FBR Capital Mkt Perform $14 → $10
Feb-23-16Downgrade Morgan Stanley Equal-Weight → Underweight
Feb-23-16Downgrade Barclays Overweight → Equal Weight $12 → $6
Feb-22-16Downgrade Citigroup Buy → Neutral
Dec-29-15Downgrade JP Morgan Overweight → Neutral $65 → $15
Dec-28-15Reiterated Piper Jaffray Overweight $63 → $10
Dec-28-15Downgrade FBR Capital Outperform → Mkt Perform $73 → $14
Dec-17-15Initiated UBS Buy $55
Oct-05-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-03-15Initiated Citigroup Buy
Aug-18-15Initiated FBR Capital Outperform $73
Aug-06-15Reiterated Brean Capital Buy $50 → $57
May-11-15Reiterated Brean Capital Buy $45 → $50
Mar-04-15Initiated Barclays Overweight $55
Feb-12-15Reiterated Stifel Buy $47 → $57
Dec-31-14Reiterated Brean Capital Buy $33 → $45
Jul-08-14Resumed Brean Capital Buy $33
Aug-03-20 08:00AM  
Jul-15-20 12:22PM  
Jul-05-20 02:43PM  
Jun-22-20 07:00AM  
Jun-18-20 08:00AM  
May-28-20 08:00AM  
May-12-20 06:47AM  
May-07-20 10:25AM  
May-02-20 08:40AM  
Apr-29-20 07:00AM  
Apr-28-20 04:30PM  
Mar-26-20 08:18AM  
Mar-18-20 06:26AM  
Feb-28-20 12:00PM  
Feb-26-20 08:00AM  
Feb-25-20 07:00AM  
Feb-24-20 08:00AM  
Feb-18-20 08:00AM  
Feb-06-20 07:04AM  
Feb-05-20 11:52AM  
Jan-29-20 08:00AM  
Jan-03-20 11:30AM  
Dec-23-19 06:12AM  
Dec-16-19 01:04AM  
Dec-14-19 08:59PM  
Dec-10-19 07:30AM  
Dec-04-19 01:01AM  
Nov-22-19 12:02AM  
Nov-07-19 06:19AM  
Nov-05-19 07:00AM  
Nov-04-19 04:01PM  
Oct-29-19 08:00AM  
Oct-02-19 08:47AM  
Oct-01-19 08:10AM  
Sep-30-19 07:30PM  
Sep-27-19 08:00AM  
Aug-27-19 01:13PM  
Aug-08-19 09:35AM  
Aug-07-19 10:30AM  
Aug-05-19 07:55AM  
Jul-31-19 07:00AM  
Jul-12-19 03:07PM  
Jun-28-19 06:41PM  
May-17-19 08:18AM  
May-16-19 09:11AM  
May-09-19 09:25AM  
May-02-19 04:01PM  
Apr-29-19 10:31AM  
Apr-12-19 01:43PM  
Apr-09-19 11:21AM  
Apr-08-19 05:00PM  
Apr-05-19 02:14PM  
Mar-26-19 06:30PM  
Mar-07-19 12:24PM  
Mar-05-19 07:00AM  
Mar-04-19 08:00AM  
Feb-26-19 08:00AM  
Feb-22-19 08:00AM  
Feb-14-19 08:15AM  
Feb-11-19 07:55AM  
Feb-06-19 02:20PM  
Jan-30-19 11:51AM  
Jan-24-19 10:17AM  
Jan-18-19 06:36AM  
Jan-17-19 09:38AM  
Jan-04-19 07:30AM  
Dec-27-18 09:23AM  
Dec-22-18 04:43AM  
Dec-18-18 08:35AM  
Dec-12-18 11:26AM  
Dec-03-18 07:55AM  
Nov-08-18 07:44AM  
Nov-07-18 08:14AM  
Nov-05-18 02:29PM  
Nov-01-18 08:00AM  
Oct-27-18 01:00PM  
Oct-24-18 07:25AM  
Oct-11-18 04:01PM  
Oct-05-18 07:00AM  
Oct-04-18 07:00AM  
Sep-26-18 07:30AM  
Sep-04-18 02:38PM  
Aug-29-18 07:00AM  
Aug-28-18 07:30AM  
Aug-08-18 09:50AM  
Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEMSKI MARTHA JDirectorAug 05Option Exercise3.162,5007,9002,500Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 05Sale3.272,5008,1870Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 04Option Exercise3.165,00015,8005,000Aug 06 12:55 PM
DEMSKI MARTHA JDirectorAug 04Sale3.255,00016,2500Aug 06 12:55 PM
Andriole Michael T.Chief Business OfficerMar 16Buy1.4333,30047,522149,729Mar 17 11:58 AM
MIDDLETON FRED ADirectorMar 12Buy1.4050,00069,900197,523Mar 16 12:19 PM
Sherman Michael A.Chief Executive OfficerMar 12Buy1.4572,995105,653102,995Mar 16 12:51 PM
Nichols GarrettChief Medical OfficerFeb 10Sale1.688,80514,830260,066Feb 11 04:19 PM
Nichols GarrettChief Medical OfficerFeb 07Sale1.702,5504,335268,871Feb 11 04:19 PM
Jakeman DavidPrincipal Accounting OfficerFeb 07Sale1.702,2903,89387,876Feb 11 04:16 PM
Nichols GarrettChief Medical OfficerJan 07Sale2.1530,68066,045271,421Jan 08 08:18 PM
MIDDLETON FRED ADirectorNov 13Buy1.8230,00054,567147,523Nov 13 04:14 PM
MIDDLETON FRED ADirectorNov 11Buy1.6620,00033,190117,523Nov 13 04:14 PM
Meyer Robert J.DirectorNov 06Buy1.5810,00015,79710,000Nov 06 05:00 PM
Andriole Michael T.Chief Business OfficerNov 06Buy1.56100,000156,000100,000Nov 07 12:45 PM